CBLB Regulates MAPK-P38 Pathway via MAP3K9 Ubiquitination to Inhibit GBM Cell Invasion and Migration

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Glioblastoma (GBM) is highly invasive and resistant to standard treatments, leading to poor prognosis.
• The ubiquitin-proteasome system (UPS) regulates protein degradation and is implicated in GBM progression.
• Identifying novel therapeutic targets within the UPS is crucial for improving GBM treatment outcomes.

Purpose of the Study:

• To investigate the role of E3 ubiquitin ligase CBLB in glioblastoma (GBM).
• To elucidate the molecular mechanism by which CBLB affects GBM cell aggressiveness.
• To assess the therapeutic potential of targeting CBLB in GBM.

Main Methods:

• Analysis of CBLB expression in GBM tissues and correlation with clinical data.
• In vitro and in vivo experiments to assess the effect of CBLB on GBM cell migration and invasion.
• Co-immunoprecipitation and ubiquitination assays to determine the interaction between CBLB and MAP3K9.
• Western blotting to analyze protein levels and pathway activation.

Main Results:

• CBLB was significantly downregulated in GBM compared to normal brain tissue, correlating with malignancy and poor prognosis.
• CBLB overexpression inhibited GBM cell migration and invasion in vitro and in vivo.
• CBLB directly interacted with MAP3K9, promoting its K48-K63-linked polyubiquitination and subsequent proteasomal degradation.
• MAP3K9 downregulation by CBLB led to suppressed activation of the MAPK-P38 signaling pathway.

Conclusions:

• CBLB functions as a tumor suppressor in GBM by inhibiting cell invasion and migration.
• The mechanism involves CBLB-mediated ubiquitination and degradation of MAP3K9, thereby modulating the MAPK-P38 pathway.
• CBLB represents a promising novel therapeutic target for GBM treatment.